Bristol Myers Squibb (NYSE:BMY) Stock Rating Lowered by Zacks Research

Bristol Myers Squibb (NYSE:BMY) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a note issued to investors on Thursday, Zacks reports.

A number of other equities research analysts also recently issued reports on BMY. Wall Street Zen raised shares of Bristol Myers Squibb from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 27th. Citigroup reissued a “neutral” rating and set a $70.00 target price (up from $66.00) on shares of Bristol Myers Squibb in a research report on Monday, August 3rd. Royal Bank Of Canada restated a “sector perform” rating on shares of Bristol Myers Squibb in a research note on Monday. Wells Fargo & Company reduced their target price on Bristol Myers Squibb from $65.00 to $60.00 and set an “equal weight” rating for the company in a report on Tuesday, October 13th. Finally, Weiss Ratings raised Bristol Myers Squibb from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, August 18th. Two investment analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating, sixteen have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average target price of $64.88.

Bristol Myers Squibb Stock Down 2.3%

Shares of NYSE:BMY opened at $61.58 on Thursday. Bristol Myers Squibb has a 12-month low of $42.52 and a 12-month high of $68.64. The company has a quick ratio of 1.38, a current ratio of 1.53 and a debt-to-equity ratio of 1.89. The stock has a market cap of $125.79 billion, a price-to-earnings ratio of 13.56, a PEG ratio of 0.32 and a beta of 0.19. The business’s 50 day moving average is $63.26 and its 200 day moving average is $60.33.

Bristol Myers Squibb (NYSE:BMY) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $2.04 EPS for the quarter, beating the consensus estimate of $1.60 by $0.44. Bristol Myers Squibb had a net margin of 18.87% and a return on equity of 66.90%. The company had revenue of $12.97 billion during the quarter, compared to the consensus estimate of $11.74 billion. During the same quarter in the prior year, the company posted $1.46 earnings per share. The firm’s revenue for the quarter was up 5.7% on a year-over-year basis. Bristol Myers Squibb has set its FY 2026 guidance at 6.750-7.000 EPS. On average, sell-side analysts forecast that Bristol Myers Squibb will post 6.56 earnings per share for the current fiscal year.

Insider Buying and Selling at Bristol Myers Squibb

In other news, SVP Phil M. Holzer sold 500 shares of the firm’s stock in a transaction that occurred on Tuesday, August 25th. The shares were sold at an average price of $67.50, for a total transaction of $33,750.00. Following the completion of the sale, the senior vice president owned 16,862 shares in the company, valued at $1,138,185. This trade represents a 2.88% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 0.05% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bristol Myers Squibb

Several institutional investors have recently bought and sold shares of the company. Compass Ion Advisors LLC boosted its holdings in shares of Bristol Myers Squibb by 28.7% in the third quarter. Compass Ion Advisors LLC now owns 4,829 shares of the biopharmaceutical company’s stock worth $301,000 after acquiring an additional 1,077 shares during the period. Radnor Capital Management LLC lifted its holdings in Bristol Myers Squibb by 0.3% during the 3rd quarter. Radnor Capital Management LLC now owns 79,483 shares of the biopharmaceutical company’s stock worth $4,960,000 after purchasing an additional 250 shares in the last quarter. Invested Advisors boosted its stake in Bristol Myers Squibb by 10.6% in the 3rd quarter. Invested Advisors now owns 8,007 shares of the biopharmaceutical company’s stock worth $500,000 after purchasing an additional 766 shares during the period. Bernardo Wealth Planning LLC bought a new position in Bristol Myers Squibb in the 3rd quarter worth about $461,000. Finally, Signaturefd LLC grew its holdings in Bristol Myers Squibb by 1.2% during the 3rd quarter. Signaturefd LLC now owns 97,541 shares of the biopharmaceutical company’s stock valued at $6,087,000 after buying an additional 1,195 shares in the last quarter. Hedge funds and other institutional investors own 76.41% of the company’s stock.

Key Bristol Myers Squibb News

Here are the key news stories impacting Bristol Myers Squibb this week:

• Positive Sentiment: Bristol Myers and SystImmune reported that izalontamab brengitecan reduced the risk of disease progression or death by 59% versus chemotherapy in the Phase 3 PANKU-Breast01 trial for advanced HR-positive/HER2-negative breast cancer. The result could strengthen BMY’s oncology pipeline and support a future regulatory filing. Bristol Myers, SystImmune drug cuts breast cancer progression risk in study
• Positive Sentiment: BMY expanded its multi-year collaboration with Tempus AI, licensing multimodal oncology data through 2031 to aid target discovery and drug development. Separately, BMS is collaborating with Pathos AI and Tempus on AI-driven research in Alzheimer’s disease and other neurological conditions, while leading Pathos’s Series E financing and gaining access to its Foundry platform. These deals may improve research productivity and pipeline potential, although financial benefits are longer term. Tempus Expands Strategic Collaboration with Bristol Myers Squibb Pathos AI Announces Strategic Collaborations
• Positive Sentiment: Analyst H. Engel modestly raised Erste Group’s FY2027 EPS forecast to $6.56 from $6.53, matching consensus and suggesting stable expectations for BMY’s earnings power. Bristol Myers Squibb analyst estimate update
• Neutral Sentiment: Phase 1 Breakfree-2 data for the CAR-T therapy zolacabtagene autoleucel in highly active multiple sclerosis provide another pipeline catalyst, but the early-stage study still requires larger and later-stage testing before its commercial value can be assessed. Bristol Myers Squibb Presents Breakfree-2 Results
• Negative Sentiment: Bristol Myers disclosed a patient death in the early-stage cell-therapy study. Even if the event does not ultimately change the program’s development, it introduces a safety overhang and may overshadow the positive efficacy data. Bristol Myers discloses patient death in early-stage cell therapy study
• Negative Sentiment: Pre-earnings coverage anticipates a year-over-year decline in third-quarter earnings, keeping attention on legacy-drug erosion, pipeline execution and BMY’s relatively high debt load. These concerns could outweigh the company’s inexpensive valuation and attractive dividend in the near term. Earnings Preview: Bristol Myers Squibb Q3 Earnings Expected to Decline

Bristol Myers Squibb Company Profile

Bristol Myers Squibb (NYSE:BMY) is a global biopharmaceutical company focused on discovering, developing and commercializing medicines for serious diseases. Its research and development activities span oncology, hematology, immunology, cardiovascular disease, neuroscience and other specialty areas.

The company’s portfolio includes oncology medicines such as Opdivo, Yervoy, Abraxane, Sprycel and Pomalyst, as well as Eliquis, an anticoagulant developed in partnership with Pfizer. Bristol Myers Squibb also markets immunology and neuroscience products, including Orencia and Sotyktu, and continues to invest in therapies based on biologics, cell therapy and other advanced treatment approaches.

Bristol Myers Squibb traces its roots to pharmaceutical businesses founded by Bristol-Myers in 1881 and E.R.